MYOTROPHIN T-IND EXPANDED TO A TOTAL OF 450 PATIENTS; ADVISORY COMMITTEE DOES NOT FIND ARGUMENTS FOR FUNDAMENTAL EFFECT ON ALS PROGRESSION COMPELLING
Executive Summary
Cephalon/Chiron's Myotrophin has been shipped to 205 amyotrophic lateral sclerosis patients under a Treatment IND, Cephalon VP-Clinical Operations William Graney, MD, told FDA's Peripheral & Central Nervous System Drugs Advisory Committee during its review of the Myotropin NDA (20-654) May 8.